



CANNON BUILDING
861 SILVER LAKE BLVD., SUITE 203
DOVER, DELAWARE 19904-2467

STATE OF DELAWARE
OFFICE OF CONTROLLED SUBSTANCES

TELEPHONE: (302) 744-4500
FAX: (302) 739-2711
WEBSITE: DPR.DELAWARE.GOV
EMAIL: customerservice.dpr@state.de.us

PUBLIC MEETING NOTICE:	CONTROLLED SUBSTANCE "Regulatory" COMMITTEE
DATE AND TIME:	Wednesday, November 5, 2014 at 9:00 a.m.
PLACE:	Buena Vista Conference Center, Dining Room, First Floor, 661 S. DuPont Highway, New Castle, Delaware 19720
APPROVED:	APPROVED May 27, 2015

MEMBERS PRESENT

Michael Kremer, DMD, Dental Representative, President
Stephen Ruggles, PA-C, PA Representative
Philip Kim, M.D., Medical Representative
Jo Ann M. Baker, MSN, RN, FNP-C, Nursing Representative
David W. Dryden, R.Ph., J.D., Director, Office of Controlled Substances

MEMBERS ABSENT

None

DIVISION STAFF/DEPUTY ATTORNEY GENERAL

Christine Mast, Administrative Specialist III
Michelle McCreary, Pharmacy Compliance Officer
Eileen Kelly, Deputy Attorney General
David Mangler, Director, Division Professional Regulation

ALSO PRESENT

Art Jankowski, VMD, Veterinary Representative
Hooshang Shanehsaz, DPS

CALL TO ORDER

Mr. Dryden called the meeting to order at 9:55 am.

DISCUSSED PROPOSED RULES AND REGULATIONS

Mr. Dryden opened the meeting to discussions regarding "Safe Opioid Prescribing" procedures. Mr. Dryden provided an initial draft of possible rules and regulations to support these procedures for the committee to review as potential regulations in the future to guide practitioners (registrants) in safe prescribing practices of controlled substances. The draft was provided to stakeholders for review and comments and feedback has been received. The comments and feedback received were provided to the committee for review and discussion to take into consideration. Mr. Mangler stated that he had not received any comments from the Medical Society, he did however receive comments and communications from members of PDAC, Oncology Society, Manufacturers, and Patient Advocates.

Mr. Dryden also stated that the drafts could and should be shared with any stakeholder who would like to provide feedback during the creation of possible rules and regulations changes related to this issue.

Mr. Dryden expressed to the committee that this is crucial to the safety of patient care. It should be as encompassing as possible for the many specialized patient care needs that utilize controlled substances.

Dr. Kremer expressed that there are two topics that should be considered and defined separately; Short Term Care and Long Term Care treatment options.

The committee reviewed the draft documents and offered the following input and suggestions:

Definitions:

Practitioner: remove Veterinarian

Add: Definitions to define: Acute Care, and Chronic to include specific duration periods and standards.

The committee suggested that the following should be considered for exemption from Regulation 11.0: Hospice Care, Active Cancer Treatment, Active Cancer related pain, terminal illness treatment.

The committee reviewed each draft regulation in order and discussed and provided input for changes or corrections that may be needed. Changes discussed within the draft regulations discussions will be updated according to the requests of the committee. Updated draft regulations formulated by this committee meeting and feedback received will be presented at the next scheduled Controlled Substance Committee meeting for review and discussion.

PUBLIC COMMENT

None

NEXT SCHEDULED MEETING

The next regular meeting of the Regulatory Committee will be announced after the next scheduled Controlled Substance Committee meeting.

ADJOURNMENT

A motion was made by Mr. Ruggles and seconded by Ms. Baker, to adjourn the meeting. The motion unanimously carried. The meeting adjourned at 11:20 am.

Respectfully submitted,



Christine Mast
Administrative Specialist III
Office of Controlled Substances